Comerica Bank Has $3.74 Million Stake in Bio-Rad Laboratories, Inc. $BIO

Key Points

• Comerica Bank cut its position in Bio‑Rad by 35.3%, selling 6,747 shares and leaving a holding of 12,350 shares valued at about $3.74 million.
• Bio‑Rad reported a Q1 EPS miss of $1.89 versus ~$1.97 consensus while revenue of $592.1M slightly beat and rose ~1.1% YoY, but management trimmed FY‑2026 guidance to roughly $2.5–$2.6 billion, sending the stock down ~8.7%.
• Analysts have cut ratings and price targets (Citigroup, Wells Fargo, Wall Street Zen), leaving a MarketBeat consensus of Hold with an average price target of $333 and institutional ownership around 65%.

Comerica Bank trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 35.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,350 shares of the medical research company's stock after selling 6,747 shares during the period. Comerica Bank's holdings in Bio-Rad Laboratories were worth $3,742,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in BIO. Quent Capital LLC acquired a new position in Bio-Rad Laboratories during the third quarter worth $25,000. Farther Finance Advisors LLC increased its holdings in shares of Bio-Rad Laboratories by 52.9% in the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company's stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. CWM LLC increased its holdings in shares of Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company's stock valued at $57,000 after purchasing an additional 91 shares during the last quarter. Finally, UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company's stock valued at $58,000 after purchasing an additional 40 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Citigroup downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating on the stock in a report on Friday. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $333.00.

Bio-Rad Laboratories Stock Down 8.7%

BIO stock opened at $255.70 on Friday. The stock has a market capitalization of $6.90 billion, a P/E ratio of 42.12 and a beta of 1.06. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $343.12. The firm has a 50-day moving average price of $277.81 and a 200-day moving average price of $298.17.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The company had revenue of $592.10 million during the quarter, compared to the consensus estimate of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.52% and a net margin of 6.52%.The firm's revenue was up 1.1% compared to the same quarter last year. During the same period last year, the company posted $2.54 EPS. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Key Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Revenue/operational positives — Q1 revenue of $592.1M slightly beat the consensus (~$590M) and revenue was up ~1.1% year‑over‑year; the company still shows a strong net margin (~29%). These factors provide some support versus a pure earnings shock. MarketBeat Q1 Release
• Neutral Sentiment: Analyst action — Wells Fargo cut its price target from $320 to $290 but kept an "equal weight" rating; the new PT still implies upside versus the current share level, which moderates the negative read on the name. Benzinga
• Neutral Sentiment: Full earnings call transcript now available — details on segment drivers, margin commentary and near‑term cadence are in the call and may clarify management's guidance changes for investors. Earnings Call Transcript
• Negative Sentiment: EPS miss — Q1 EPS was $1.89, below consensus (about $1.97) and down from $2.54 a year earlier, a clear earnings disappointment that weighed on sentiment. Zacks
• Negative Sentiment: Guidance cut — Management trimmed its FY‑2026 outlook, issuing revenue guidance of about $2.5B–$2.6B versus consensus nearer the top of that range; the company explicitly lowered its outlook, which is the main driver of the share decline. TipRanks

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.